BMS Names New Board Member - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BMS Names New Board Member



Bristol-Myers Squibb’s board of directors has elected Thomas J. Lynch, Jr., MD to its board, effective Jan. 1, 2014. Lynch will serve as a member of the Science and Technology Committee of the Board of Directors.

Lynch is currently the director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven. He is also the Richard Sackler and Jonathan Sackler Professor of Medical Oncology at Yale-New Haven. He has held these positions since 2009. From 1993 to 2009, he was a professor of medicine at Harvard Medical School and chief of hematology and oncology at Massachusetts General Hospital (MGH) Cancer Center. He also served as director of the Center for Thoracic Cancers at MGH and director of medical oncology at the MGH Thoracic Oncology Center.

Source: Bristol-Myers Squibb

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here